Victory Capital Management Inc. Cuts Stake in Aclaris Therapeutics, Inc. (ACRS)

Victory Capital Management Inc. trimmed its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 1.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 41,021 shares of the biotechnology company’s stock after selling 440 shares during the period. Victory Capital Management Inc. owned approximately 0.15% of Aclaris Therapeutics worth $1,112,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. FMR LLC raised its holdings in Aclaris Therapeutics by 253.1% during the first quarter. FMR LLC now owns 1,653,937 shares of the biotechnology company’s stock worth $49,321,000 after acquiring an additional 1,185,598 shares in the last quarter. MARSHALL WACE ASIA Ltd bought a new stake in Aclaris Therapeutics in the first quarter valued at approximately $21,116,000. Marshall Wace North America L.P. bought a new stake in Aclaris Therapeutics in the first quarter valued at approximately $21,116,000. Point72 Asset Management L.P. bought a new stake in Aclaris Therapeutics in the first quarter valued at approximately $13,715,000. Finally, Loomis Sayles & Co. L P bought a new stake in Aclaris Therapeutics in the first quarter valued at approximately $11,927,000. Institutional investors own 95.79% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Victory Capital Management Inc. Cuts Stake in Aclaris Therapeutics, Inc. (ACRS)” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/15/victory-capital-management-inc-cuts-stake-in-aclaris-therapeutics-inc-acrs.html.

Aclaris Therapeutics, Inc. (NASDAQ ACRS) opened at 26.44 on Friday. The company’s market capitalization is $706.90 million. The stock has a 50 day moving average price of $26.28 and a 200-day moving average price of $27.75. Aclaris Therapeutics, Inc. has a 52 week low of $20.15 and a 52 week high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.12. On average, equities analysts predict that Aclaris Therapeutics, Inc. will post ($3.10) earnings per share for the current fiscal year.

In other Aclaris Therapeutics news, Director Andrew N. Schiff purchased 108,601 shares of the stock in a transaction on Wednesday, August 16th. The stock was acquired at an average cost of $23.02 per share, with a total value of $2,499,995.02. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 16.30% of the stock is currently owned by insiders.

Several analysts have issued reports on the company. ValuEngine lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. JMP Securities reaffirmed an “outperform” rating and issued a $39.00 target price on shares of Aclaris Therapeutics in a research report on Friday, September 8th. BidaskClub raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. Cantor Fitzgerald set a $50.00 target price on Aclaris Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $36.00 target price on shares of Aclaris Therapeutics in a research report on Monday, July 31st. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $40.00.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics, Inc. (NASDAQ:ACRS).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply